- Home
- GNL vs MYGN Comparison
GNL vs MYGN Comparison
Compare GNL & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNL | MYGN |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 481.6M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | GNL | MYGN |
|---|---|---|
| Price | $9.39 | $4.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $9.50 | $7.64 |
| AVG Volume (30 Days) | ★ 1.8M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $6.51 | $3.76 |
| 52 Week High | $10.04 | $10.32 |
Technical Indicators
Market Signals| Indicator | GNL | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 41.35 |
| Support Level | $9.23 | $3.93 |
| Resistance Level | $9.66 | $5.63 |
| Average True Range (ATR) | 0.22 | 0.42 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 35.61 | 21.43 |
Price Performance
Historical ComparisonAbout GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.